Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer-Reference-Cited by-同舟云学术

Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer

Published:2002-10-18 Issue:11 Volume:9 Page:935-945
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Bennett Joseph J,Delman Keith A,Burt Bryan M,Mariotti Adam,Malhotra Sandeep,Zager Jonathan,Petrowsky Henrik,Mastorides Stephen,Federoff Howard,Fong Yuman

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/7700510.pdf

Reference46 articles.

1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM . Experimental therapy of human glioma by means of a genetically engineered virus mutant Science 1991 252: 854–856

2. Jia WW, McDermott M, Goldie J, Cynader M, Tan J, Tufaro F . Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1 (see comments) J Natl Cancer Inst 1994 86: 1209–1215

3. Mineta T, Rabkin SD, Martuza RL . Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant Cancer Res 1994 54: 3963–3966

4. Goldstein DJ, Weller SK . Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant J Virol 1988 62: 196–205

5. Goldstein DJ, Weller SK . Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant Virology 1988 166: 41–51

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies;Cancers;2023-11-30

2. Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment;Cancers;2023-10-23

3. HSV: The scout and assault for digestive system tumors;Frontiers in Molecular Biosciences;2023-02-28

4. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles;International Journal of Molecular Sciences;2023-02-12

5. Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model;Viruses;2023-01-27